Monnier Jilliana, Georgin-Lavialle Sophie, Canioni Danielle, Lhermitte Ludovic, Soussan Michael, Arock Michel, Bruneau Julie, Dubreuil Patrice, Bodemer Christine, Chandesris Marie-Olivia, Lortholary Olivier, Hermine Olivier, Damaj Gandhi
Service de Médecine Interne, Hôpital Tenon, Université Paris VI, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Centre de Référence des Mastocytoses, Faculté de Médecine et AP-HP Necker-Enfants Malades, Paris, France.
Oncotarget. 2016 Oct 4;7(40):66299-66309. doi: 10.18632/oncotarget.11812.
Mast cell sarcoma (MCS) is a rare form of mastocytosis characterized by the presence of solid tumor(s) comprising malignant mast cells that harbor destructive infiltration capability and metastatic potential. Here, we present an extensive literature review and report on 23 cases of MCS, including 3 new cases from the French National Reference Center for Mastocytosis. From our analysis, it appears that MCS can occur at any age. It can manifest de novo or, to a lesser extent, may evolve from a previously established mastocytosis. Bone tumor is a frequent manifestation, and symptoms of mast cell activation are rare. Histological diagnosis can be difficult because MCS is frequently composed of highly atypical neoplastic mast cells and can thus mimic other tumors. Unexpectedly, the canonical KIT D816V mutation is found in only 21% of MCS; therefore, complete KIT gene sequencing is required. The prognosis of patients with MCS is poor, with a median survival time of less than 18 months, and progression to mast cell leukemia is not unusual. Because conventional chemotherapies usually fail, the role of targeted therapies and bone marrow transplantation warrants further investigation in such aggressive neoplasms.
肥大细胞肉瘤(MCS)是肥大细胞增多症的一种罕见形式,其特征是存在由具有破坏性浸润能力和转移潜能的恶性肥大细胞组成的实体瘤。在此,我们对23例MCS进行了广泛的文献综述并报告,其中包括来自法国国家肥大细胞增多症参考中心的3例新病例。通过我们的分析,似乎MCS可发生于任何年龄。它可原发出现,或在较小程度上,可能由先前已确诊的肥大细胞增多症演变而来。骨肿瘤是常见表现,而肥大细胞活化症状罕见。组织学诊断可能困难,因为MCS常由高度非典型的肿瘤性肥大细胞组成,因此可模仿其他肿瘤。出乎意料的是,仅21%的MCS中发现了典型的KIT D816V突变;因此,需要进行完整的KIT基因测序。MCS患者的预后较差,中位生存时间不到18个月,进展为肥大细胞白血病并不罕见。由于传统化疗通常无效,靶向治疗和骨髓移植在这种侵袭性肿瘤中的作用值得进一步研究。